DNA

IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid…

1 year ago

Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)

Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics ApplicationsSAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Telesis Bio…

1 year ago

Sotera Health to Present at the 2023 RBC Capital Markets Global Healthcare Conference

CLEVELAND, May 12, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global…

1 year ago

Assure Holdings Corp. Announces Pricing of $6 Million Underwritten Public Offering

DENVER, May 12, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (NASDAQ: IONM) (“Assure Holdings” or the “Company”), a provider of…

1 year ago

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in…

1 year ago

Bio-Path Holdings Reports First Quarter 2023 Financial Results

Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),…

1 year ago

Jushi Holdings Inc. Reports First Quarter 2023 Financial Results

Total Revenue of $69.9 Million, an increase of 12.9% YoY Net Loss of $12.4 Million, an improvement of 37.0% YoY…

1 year ago

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no…

1 year ago

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel…

1 year ago

IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update

Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins…

1 year ago